To Evaluate Efficacy of Monotherapy of Oxcarbazepine Versus Combination of Gabapentin With Oxcarbazepine in the Management of Trigeminal Neuralgia

by palligoelme@gmail.com | Jun 4, 2026 | Clinical Trials

​ Conditions: Effectiveness of Drugs Was Compared for Treating Trigeminal Neuralgia; Pain; Pain Management Interventions: Drug: oxcarbamezapine(300 mg twice daily); Drug: combination therapy(oxcarbamezapine 300 mg twice daily and gabapentine) Sponsors: Rehman Medical...

Pitavastatin With Ezetimibe Combination Therapy Versus High-intensity Statin in Older Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

by palligoelme@gmail.com | Jun 4, 2026 | Clinical Trials

​ Conditions: Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI); Coronary Artery Disease Interventions: Drug: Pitavastatin/ezetimibe; Drug: High-Intensity Statins Sponsors: Samsung Medical Center Not yet recruiting Conditions: Acute...

Imaging CRF X NOP Interactions in Alcohol Use Disorder

by palligoelme@gmail.com | Jun 3, 2026 | Clinical Trials

​ Conditions: Alcohol Use Disorder Interventions: Radiation: Baseline [C-11]NOP-1A PET scan; Drug: Hydrocortisone; Radiation: Post-hydrocortisone [C-11]NOP-1A PET scan Sponsors: Rajesh Narendran; National Institute on Alcohol Abuse and Alcoholism (NIAAA)...

cRCT of AI Agent in Clinital Resoning Training

by palligoelme@gmail.com | Jun 3, 2026 | Clinical Trials

​ Conditions: Medical Education; Clinical Reasoning; AI Agent Interventions: Other: AI agent; Other: Study materials Sponsors: Peking Union Medical College Hospital Enrolling by invitation Conditions: Medical Education; Clinical Reasoning; AI Agent Interventions:...

Feasibility of a Community-Based Multimodal Exercise Programme in Parkinson’s Disease

by palligoelme@gmail.com | Jun 3, 2026 | Clinical Trials

​ Conditions: PARKINSON DISEASE (Disorder) Interventions: Other: Exercise Group Sponsors: Universidad Rey Juan Carlos; Asociación Parkinson Madrid Recruiting Conditions: PARKINSON DISEASE (Disorder) Interventions: Other: Exercise Group Sponsors: Universidad Rey Juan...

Determination 2 – Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

by palligoelme@gmail.com | Jun 3, 2026 | Clinical Trials

​ Conditions: Multiple Myeloma Interventions: Drug: Isatuximab; Drug: Iberdomide; Drug: Bortezomib (B); Drug: Dexamethasone; Drug: Melphalan; Drug: Linvoseltamab; Device: On Body Delivery System (OBDS) Sponsors: Dana-Farber Cancer Institute; Sanofi; Bristol-Myers...